Foamix Pharmaceuticals Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Foamix Pharmaceuticals Ltd (FOMX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Foamix Pharmaceuticals Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 5M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-88.0% annualized vs trailing 12 months).
- Peer revenue share: Foamix Pharmaceuticals Ltd accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
FOMX Sales vs. its Competitors, Q4 2019
Foamix Pharmaceuticals Ltd generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Legal Cannabis industry grew revenue 35.0% year over year, combined, vs -84.3% for Foamix Pharmaceuticals Ltd. Foamix Pharmaceuticals Ltd's share of combined industry revenue moved from 0.04% to 0.00%, a loss of 0.03 percentage points.